Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon
Impella ECP heart pump insertion Abiomed Johnson & Johnson MedTech

Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

The Impella ECP heart pump, which measures at just 3 mm in length, was linked to positive safety data in a new study presented at TCT 2024.

EARLY TAVR investigator Philippe Généreux, MD, announced his team’s findings in front of a packed audience at TCT 2024.

Treating asymptomatic aortic stenosis with TAVR linked to significant benefits

Attendees cheered as lead investigator Philippe Généreux, MD, shared his team's findings at TCT 2024. “A major reset in our approach to severe asymptomatic AS is now warranted,” one veteran cardiologist said about the data. “The concept of watchful waiting is no longer appropriate."

New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

HeartFlow sharing new data on AI-enabled CAD management at TCT 2024

The California-based company, fresh off receiving expanded Medicare coverage and a new Category I CPT code for its AI offerings, will have a significant presence at TCT 2024. 

TCT 2023 crowd

CRF announces late-breaking clinical trials for TCT 2024

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

With a growing shortage of cardiologists in the U.S., there is growing interest recruiting more clinicians from overseas. But there are barriers to this, approach explained Abdel Almanfi, MD, FACC, FSCAI, a structural heart interventional cardiologist at Baylor St. Luke's Medical Center in Houston, Texas. He spoke with Cardiovascular Business and shared his journey from Libya to the United States, shedding light on the challenges foreign doctors face in realizing their dreams of practicing in America.

Cardiologist shares his long journey from Libya to United States

Abdel Almanfi, MD, went through years of training in Libya, but then he had to start over once he landed in the United States. 

Boston Scientific’s Agent Drug-Coated Balloon (DCB), which delivers a therapeutic dose of the anti-proliferative drug paclitaxel to the patient’s scar tissue to prevent ISR from recurring, gained FDA approval on March 1..

Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

Carrie Redick RN MSN NEA-BC, director of interventional cardiology and structural heart, Morristown Medical Center, Atlantic Health System, explains the need for financial literacy among structural heart program directors at the Transcatheter Cardiovascular therapeutics (TCT) 2023 meeting.

Why financial literacy is so important for structural heart program directors

Carrie Redick, an ICU nurse for nearly 20 years, said understanding more about financial data improved her ability to acquire funding and other resources for her program when necessary. 

Displaying 17 - 24 of 112
Design by Adaptive Theme